Kranjčec Bojana, Papeš Dino, Altarac Silvio
Department of Medical Biochemistry, Zabok General Hospital, Zabok, Croatia.
World J Urol. 2014 Feb;32(1):79-84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30.
To test whether D-mannose powder is effective for recurrent urinary tract infection (UTI) prevention.
After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis.
Overall 98 patients (31.8%) had recurrent UTI: 15 (14.6) in the D-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P < 0.001). Patients in D-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P < 0.0001). In active groups, 17.9% of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in D-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P < 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated.
In our study, D-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that D-mannose may be useful for UTI prevention.
测试D-甘露糖粉对预防复发性尿路感染(UTI)是否有效。
在对急性膀胱炎进行初始抗生素治疗后,308名有复发性UTI病史且无其他重大合并症的女性被随机分为三组。第一组(n = 103)每天服用2克D-甘露糖粉,溶于200毫升水中,持续6个月;第二组(n = 103)每天服用50毫克呋喃妥因;第三组(n = 102)不进行预防治疗。
总体上,98名患者(31.8%)出现复发性UTI:D-甘露糖组15例(14.6%),呋喃妥因组21例(20.4%),未预防组62例(60.8%),未预防组的复发率显著高于活性治疗组(P < 0.001)。与未预防组患者相比,D-甘露糖组和呋喃妥因组患者在预防治疗期间复发性UTI发作的风险显著降低(相对风险分别为0.239和0.335,P < 0.0001)。在活性治疗组中,17.9%的患者报告有副作用,但症状轻微,无需停止预防治疗。与呋喃妥因组患者相比,D-甘露糖组患者出现副作用的风险显著降低(相对风险为0.276,P < 0.0001),但由于呋喃妥因耐受性良好,这一发现的临床意义不大。
在我们的研究中,D-甘露糖粉显著降低了复发性UTI的风险,与呋喃妥因组效果无异。需要更多研究来验证本研究结果,但初步发现表明D-甘露糖可能对预防UTI有用。